ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IPSEY Ipsen SA (PK)

31.84
-1.86 (-5.52%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Ipsen SA (PK) USOTC:IPSEY OTCMarkets Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -1.86 -5.52% 31.84 31.05 33.32 31.84 31.84 31.84 395 21:14:28

Ipsen Sells Shares In PregLem Holding SA to Gedeon Richter Plc

11/10/2010 7:07am

Dow Jones News


Ipsen (PK) (USOTC:IPSEY)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Ipsen (PK) Charts.

French pharmaceutical group Ipsen SA (IPN.FR) Monday said it sold its shares in in PregLem Holding SA to Gedeon Richter Plc (RICHTER.BU0, as have all PregLem's other shareholders.

MAIN FACTS:

- Ipsen will receive initial proceeds of CHF 6 million from the sale of its PregLem shares. Ipsen may also receive progressive additional payments of up to CHF 25 million, contingent upon the achievement of certain business development and regulatory milestones for EsmyaTM.

- The impact of this transaction will be recorded as financial income in Ipsen's accounts.

- In June 2007, the Group spun off to PregLem, then a newly-formed, privately held Swiss biopharmaceutical company, a sulfatase inhibitor and a somatostatin analogue (PGL1001 and PGL2001, respectively), patents and know-how for use in the field of human reproductive medicine.

-In parallel, Ipsen subscribed to newly issued shares of Preglem, representing a c.15 % minority interest in its share capital.

- Additionally, subject to PGL1001 and PGL2001 being granted marketing approvals, Ipsen will notably receive mid single digit royalties on PregLem's future net sales of these products.

Company Web site: www.ipsen.com

- By Paris Bureau, Dow Jones Newswires; +331-4017-1740; geraldine.amiel@dowjones.com;

 
 

1 Year Ipsen (PK) Chart

1 Year Ipsen (PK) Chart

1 Month Ipsen (PK) Chart

1 Month Ipsen (PK) Chart